An Overview of Thyroid Cancer Genetics and Inheritance

<p>Thyroid cancer (TC) is the most common endocrine malignancy and its incidence hasbeen increasing sharply since the mid-1990s [1]. TC is a general term that comprises two main groups of neoplasias, depending on the cell type affected by the malignant transformation. 1) Carcinomas originating...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Diana Navas-Carrillo (Auteur), Esteban Orenes-Pinero (Auteur)
Formaat: Boek
Gepubliceerd in: Global Journal of Cancer Therapy - Peertechz Publications, 2015-03-30.
Onderwerpen:
Online toegang:Connect to this object online.
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_gjct_000003
042 |a dc 
100 1 0 |a Diana Navas-Carrillo  |e author 
700 1 0 |a Esteban Orenes-Pinero  |e author 
245 0 0 |a An Overview of Thyroid Cancer Genetics and Inheritance 
260 |b Global Journal of Cancer Therapy - Peertechz Publications,   |c 2015-03-30. 
520 |a <p>Thyroid cancer (TC) is the most common endocrine malignancy and its incidence hasbeen increasing sharply since the mid-1990s [1]. TC is a general term that comprises two main groups of neoplasias, depending on the cell type affected by the malignant transformation. 1) Carcinomas originating from the follicular epithelium, referred to as nonmedullary thyroid cancer (NMTC) representing more than 95% of all TC; and 2) carcinomas originating from the parafollicular thyroid C cells, referred to as medullary thyroid cancer (MTC) accounting less than 5% of all TC.</p><p>Although MTC accounts only for 5% of all the thyroid cancers, it is responsible forabout 15% of all the deaths related to thyroid cancer [2]. Familial medullary thyroid carcinoma (FMTC) encompasses about 25% of all the medullary thyroid carcinomas, appearing as part of a rare inherited syndrome called multiple endocrine neoplasia 2(MEN2) or as isolated FMTC. These familial forms have in common germline gain-of function mutations in the RET proto-oncogene, located on chromosome 10q1 1.2 [2]. Almost all patients with a germline RET mutation develop c-cell hyperplasia or MTC during their lifetime. Today, about 98% of all the mutations responsible for FMTC areknown.</p> 
540 |a Copyright © Diana Navas-Carrillo et al. 
546 |a en 
655 7 |a Editorial  |2 local 
856 4 1 |u https://doi.org/10.17352/gjct.000003  |z Connect to this object online.